Neubase Therapeutics Inc 's ROA from the third quarter of 2023 to the third quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Neubase Therapeutics Inc 's ROA in the third quarter of 2023?
Neubase Therapeutics Inc recorded a cumulative net loss of $-14 million during 12 months ending in the third quarter of 2023, resulting in a negative return on assets (ROA) of -73.47%.

However, within the Healthcare sector 765 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2023 quarter, so far to 4631, from total ROA ranking in the second quarter of 2023 at 4924.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter	(Dec 31 2022) I. Quarter	(Sep 30 2022) IV. Quarter
Y / Y Total Assets Change	-33.03 %	-49.91 %	-64.93 %	-59.88 %	-56.67 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-14	-22	-27	-32	-36
Return On Assets (TTM)	-73.47 %	-102.83 %	-104.5 %	-97.17 %	-86.86 %
NBSE's Total Ranking	# 4631	# 4924	# 5114	# 5887	# 5158
Total Assets (TTM) in million	19	18	17	21	28
Seq. Total Assets Change	3.3 %	5.32 %	-18.43 %	-24.53 %	-22.74 %
Seq. Net Income Change	-	-	-	-	-

NBSE's 5 Years Annual ROA >> Back to NBSE Management Effectiveness >> Compare NBSE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 349
Sector	# 766
Overall	# 4545

Return On Assets Statistics
High	Average	Low
89.65 %	-97.98 %	-536.87 %
(Sep 30 2012)		(Sep 30 2019)

Financial Statements
Neubase Therapeutics Inc 's Assets	$ 19 million	NBSE's Balance sheet
Neubase Therapeutics Inc 's Income	$ -2 million	Quarterly NBSE's Income Statement
NBSE's Income by Division		See NBSE's Income by Division

Annual Return On Assets	(Sep 30 2022) FY 2022	(Sep 30 2021) FY 2021	(Sep 30 2020) FY 2020	(Sep 30 2019) FY 2019	(Sep 30 2018) FY 2018
Y / Y Total Assets Change	-56.67 %	86.29 %	174.86 %	7.79 %	-58.37 %
Total Assets in million	28	64	34	13	12
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-34	-25	-17	-27	-13
Annual Return On Assets	-121.47 %	-39.6 %	-50.47 %	-215.13 %	-113.85 %

NBSE's 5 Years Annual ROA >> Back to NBSE Management Effectiveness >> Compare NBSE ROA to its Competitors

More Return On Assets Ratios
NBSE's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NBSE's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NBSE's Competitors
Subscribers only: Roa for Neubase Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for NBSE's Customers

You may also want to know
NBSE's Roi	NBSE's Inventory Turnover Ratio	NBSE's Growth Rates	NBSE's Dividend Comparisons
	NBSE's Profitability Ratios	NBSE's Asset Turnover Ratio	NBSE's Dividend Growth
NBSE's Roe	NBSE's Valuation Ratios	NBSE's Financial Strength Ratios	NBSE's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2023, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:22:12+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.